Le Lézard
Classified in: Health, Science and technology, Business
Subject: LIC

Copia Scientific Enters Agreement with Leading Pharmaceutical Company


TAUNTON, Mass., April 23, 2024 /PRNewswire/ -- Copia Scientific, a provider of laboratory equipment and service solutions, is pleased to announce that it has entered into a strategic agreement with a top 10 global Fortune 50 pharmaceutical company. This collaboration marks a significant milestone for Copia Scientific and underscores its commitment to advancing scientific research and development in the pharmaceutical industry.

The agreement includes the global distribution of Certified Pre-Owned Laboratory Equipment and Service in select international sites. Leveraging Copia Scientific's expertise in Lab Automation, Lab Integration, Method Development and Service Solutions, the partnership will augment operational efficiency, increase productivity, and implement cost containment strategies through Copia Scientific's "One Vendor - One Solution" enterprise model.

"We are thrilled to partner with one of the world's leading pharmaceutical companies," said Dyan Reagan, Chief Operations Officer at Copia Scientific. "This agreement is a testament to the quality of our products and comprehensive customer support of our solutions and validates our position as a trusted partner in the pharmaceutical industry."

Copia Scientific's experienced scientists, engineers, and industry experts play a pivotal role in supporting the pharmaceutical company's initiatives to find cost efficiencies without compromising on technology, quality, reliability, and of course, the science.

About Copia Scientific: Copia Scientific is a global provider of Certified Pre-Owned (CPO) Lab Equipment and broad ranging Service Solutions. Founded in 2021 through the merger of three industry-leading companies with over 37 years of market exposure, Copia Scientific is dedicated to empowering laboratories with cost effective state-of-the-art solutions that drive efficiency and productivity.

This press release signifies another significant milestone for Copia Scientific as it strengthens its position as a leader in the laboratory solutions industry and highlights its commitment to advancing scientific research and development in collaboration with major players in the pharmaceutical sector.

For more information visit www.copiasci.com to learn more.

For media inquiries or further information, please contact: David Langlois, Marketing Manager, [email protected].

SOURCE Copia Scientific


These press releases may also interest you

at 17:25
Talphera Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Talphera, Inc. , ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that the Board of Directors of Talphera has granted...

at 16:56
JDRF-Authored Paper Shows Pathway to Accelerate Disease-Modifying Therapies for People with Type 1 Diabetes
A paper published in the June edition of the Journal Diabetes demonstrates that C-peptide, a biomarker that indicates the production of insulin, is a validated surrogate endpoint, or predictor of clinical benefit, for clinical trials of...

at 16:28
Insmed Presents Positive Patient-Reported Outcomes and Microbiologic Data from Phase 3 ARISE Study Of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with NTM Lung Disease Caused by MAC at American Thoracic Society 2024 International Conference Plenary Session
?Patients Treated with ARIKAYCE Plus Macrolide-Based Background Regimen Had Meaningfully Greater Improvements in Respiratory Symptoms vs. Macrolide-Based Background Regimen Alone, As Measured By the QOL-B Respiratory Domain Instrument? ?QOL-B...

at 16:20
TOP-RANKED HEALTHCARE CONSULTING FIRM EXPANDS ROSTER, DEEPENS LEADERSHIP
Jarrard Inc., a leading national healthcare strategic communications consultancy, has expanded by 10 percent, adding seven new professionals to address the increasing demand for its healthcare advisory services. The team now includes 81 full-time...

at 16:10
Pulse Biosciences Announces Updated Timing of Rights Offering for Up to $60,000,000
Pulse Biosciences, Inc. ("Pulse" or the "Company"), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablationtm (nsPFAtm) technology, today announced that the Company's Board of Directors has determined a new record...

at 16:10
Contineum Therapeutics Announces Appointment of Troy Ignelzi to Board of Directors
Contineum Therapeutics, Inc. , a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of...

More news about Health...


News published on and distributed by: